NANOBIOTIX Provides Business Update and Reports Full Year
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
Stay updated with breaking news from Full Year. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces...
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and
First Quarter 2024 Highlights: Net Sales $738 Million; Conversion Revenue $367 MillionNet Income $25 Million; Net Income per Diluted Share $1.51Adjusted Net Income $17 Million; Adjusted Net Income...
BOSTON - April 23, 2024 - GE Aerospace announced results today for the first quarter ending March 31, 2024. The consolidated results below include the operations of GE Vernova Inc. ,...